Soluble CD59 Gene Therapy for Geographic Atrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration (AMD), particularly geographic atrophy, lack effective solutions, as existing therapies do not adequately address the underlying complement system activation that contributes to the disease progression.
Innovation Solution
Administration of a pharmaceutical composition via ocular injection containing a nucleic acid encoding a soluble CD59 protein, packaged in an adeno-associated virus (AAV) vector, which expresses and secretes the protein to inhibit membrane attack complex formation, thereby reducing complement activity and treating AMD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If soluble CD59 protein is administered via frequent injections, then complement activity is inhibited and MAC formation is reduced, but treatment complexity and patient burden increase
Solution Approach 1:
The patent applies preliminary action by using gene therapy to establish a permanent source of soluble CD59 production within the eye. The AAV vector delivers the CD59 gene to retinal cells, which then continuously produce and secrete the protective protein, eliminating the need for repeated injections and providing sustained complement inhibition over time.
Solution Approach 2:
The patent implements self-service by enabling the patient's own retinal cells to produce and secrete soluble CD59 autonomously after gene transduction. The modified cells continuously generate the protective protein locally, creating a self-sustaining therapeutic effect that does not require external intervention or repeated administrations.
2Object-affected harmful factors
If high doses of soluble CD59 are administered frequently, then MAC deposition is effectively reduced, but treatment cost and patient burden increase
Solution Approach 1:
The patent applies continuity of useful action by establishing continuous endogenous production of soluble CD59 through gene therapy. Once the AAV vector transduces the retinal cells, they continuously synthesize and secrete the protective protein at physiological levels, providing uninterrupted complement inhibition without requiring repeated dosing sessions.
Solution Approach 2:
The patent implements self-service by enabling the patient's own retinal cells to produce and secrete soluble CD59 autonomously after gene transduction. The modified cells continuously generate the protective protein locally, creating a self-sustaining therapeutic effect that does not require external intervention or repeated administrations.
3Object-affected harmful factors
If membrane-bound CD59 is used, then MAC inhibition is effective, but the protein cannot be secreted into the vitreous to protect extracellular structures
Solution Approach 1:
The patent applies the extraction principle by removing the glycosylphosphatidylinositol (GPI) anchor sequence from the CD59 protein structure. This modification detaches the protein from membrane binding, converting it into a soluble form that can be freely secreted into the vitreous humor while retaining its MAC-inhibiting function, thus enabling protection of both intracellular and extracellular structures.
Solution Approach 2:
The patent applies parameter changes by modifying the molecular structure of CD59 through deletion of the GPI anchor domain. This structural parameter change transforms the protein from a membrane-bound state to a soluble, secretable state, enabling it to function in both intracellular and extracellular environments without losing its complement-inhibiting activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively decreases membrane attack complex deposition and slows the progression of AMD, particularly geographic atrophy, by promoting the local production and secretion of soluble CD59, offering a safer and more effective treatment compared to frequent protein injections.
Implementation Method 1
a nucleic acid encoding a soluble CD59 protein operably linked to a promoter, wherein the nucleic acid encoding sCD59 is packaged into a delivery vector
Implementation Method 2
The terminal component of the complement pathway is formation of the membrane attack complex (MAC), a complex of proteins on the cell membrane which has cytolytic functions... A natural inhibitor of the MAC complex is CD59
Data Source
AI summary
The described invention provides method for treating a complement disorder such as age-related macular degeneration (AMD) in a subject, comprising administering a pharmaceutical composition into an affected eye of a subject by ocular injection, wherein the composition comprises a nucleic acid encoding a soluble CD59 (sCD59) protein operably linked to a promoter, wherein the nucleic acid encoding sCD59 is packaged into a delivery vector and wherein the administering results in expression and secretion of the sCD59 protein by cells of the affected eye and the expression results in treatment of affected cells in the affected eye.